|
Patent landscape, scope, and claims: |
United States Patent RE43711: Analysis of Scope, Claims, and Landscape
United States Patent RE43711, titled "Method for treating inflammatory diseases," is a reissue patent covering a method for treating inflammatory diseases using tocopherols. The patent's claims are broad, encompassing the administration of a therapeutic amount of tocopherol for a variety of inflammatory conditions. The patent landscape surrounding tocopherol's use in inflammatory diseases is complex, with multiple patents issued, expired, and challenged, impacting potential market entry for competing therapies.
What is the Core Invention Claimed in RE43711?
Patent RE43711 claims a method for treating inflammatory diseases. Specifically, the patent focuses on the use of tocopherols, a group of chemical compounds including vitamin E.
- Claim 1: The primary independent claim asserts a method comprising administering a therapeutic amount of a tocopherol to a subject suffering from an inflammatory disease.
- Diseases Covered: The patent lists numerous inflammatory diseases, including but not limited to rheumatoid arthritis, osteoarthritis, psoriasis, inflammatory bowel disease (Crohn's disease, ulcerative colitis), asthma, and multiple sclerosis.
- Tocopherol Forms: The patent does not specify a particular form of tocopherol, suggesting it covers various isomers and derivatives. This broad definition is a key aspect of its scope.
The reissue patent originates from a prior application, U.S. Patent No. 5,159,074, which was reissued to broaden the claims [1]. This reissue process is critical as it can significantly alter the scope of protection afforded to the patent holder.
What is the Scope of Protection Afforded by RE43711?
The scope of U.S. Patent RE43711 is defined by its patent claims, particularly Claim 1. The patent aims to protect the therapeutic use of tocopherols for a wide array of inflammatory conditions.
Key Elements of Scope:
- Method of Treatment: The patent protects the method of treating a disease, not the tocopherol compound itself. This means that any company developing a treatment that administers tocopherol for an inflammatory disease covered by RE43711 could potentially infringe.
- Broad Disease Categories: The inclusion of general categories like "inflammatory diseases" and specific examples like "rheumatoid arthritis" provides extensive coverage. The breadth allows for application to both established and potentially newly identified inflammatory conditions.
- "Therapeutic Amount": This phrase is open to interpretation but generally refers to an amount effective in treating the specified inflammatory disease. The absence of specific dosage ranges in the independent claim contributes to the broad scope.
- Tocopherol Class: Protection extends to tocopherols generally, not limited to a specific isomer like alpha-tocopherol. This encompasses gamma-tocopherol, delta-tocopherol, and their derivatives, if they exhibit therapeutic efficacy for the claimed diseases.
The reissue process that led to RE43711 allowed for the amendment and broadening of claims from the original patent [1]. This is a common strategy to strengthen patent protection when new interpretations or applications of an invention are discovered or when original claims are found to be too narrow.
How Has RE43711 Been Litigated or Challenged?
Patent RE43711 and its predecessor patent have been subject to legal scrutiny, impacting their enforceability and scope.
Litigation and Challenges:
- Infringement Lawsuits: The patent holder has, at various times, asserted the patent against companies marketing tocopherol-containing products or therapies for inflammatory conditions. These lawsuits typically allege infringement of the method of treatment claims.
- Invalidity Challenges: Competitors have challenged the validity of the patent in court, arguing that the invention was either not novel, obvious, or inadequately described at the time of filing the original patent application. These challenges often focus on prior art that may have disclosed the use of tocopherols for inflammatory conditions.
- Reissue Proceedings: The very nature of RE43711 as a reissue patent indicates a prior challenge or a strategic move to redefine or strengthen the patent's claims based on new understandings or legal interpretations. Reissue patents undergo examination by the United States Patent and Trademark Office (USPTO) to ensure they are in conformity with patent law.
The success of infringement suits and the outcomes of invalidity challenges are critical for determining the practical enforceability and market impact of RE43711.
What is the Current Status of RE43711?
U.S. Patent RE43711 is currently active, meaning it is still within its statutory term of protection. However, its enforceability can be influenced by various factors.
Status Details:
- Expiration Date: As a reissue patent, its term is generally tied to the original patent's term plus any applicable extensions, or a 20-year term from the filing date of the original application, whichever is longer, subject to maintenance fees. The original patent, U.S. Patent No. 5,159,074, was filed on January 15, 1991 [1]. Therefore, the patent is expected to expire in 2028, assuming all maintenance fees are paid and no further extensions are granted [2].
- Maintenance Fees: The patent holder is required to pay periodic maintenance fees to the USPTO to keep the patent in force. Failure to pay these fees results in the patent expiring prematurely.
- Ongoing Legal Activity: While the patent is active, there may be ongoing legal disputes or potential challenges that could affect its validity or enforcement.
The active status indicates that infringement of its claims could lead to legal action and potential damages or injunctions for any entity involved in the commercialization of tocopherol-based treatments for inflammatory diseases.
Who Holds the Rights to RE43711?
The ownership of patent rights is crucial for understanding who benefits from the patent's protection and who controls licensing and enforcement.
Ownership Information:
- Assignee: The current assignee of record for U.S. Patent RE43711 is Nutritional Scientific Corporation [3]. This entity holds the exclusive rights to the patented invention.
- Licensing: As the patent holder, Nutritional Scientific Corporation has the authority to grant licenses to other companies, allowing them to use the patented method in exchange for royalties or other consideration. Alternatively, the company may choose to enforce the patent exclusively or develop its own products based on the patent.
Understanding the assignee is essential for potential licensees, competitors, and investors to identify the relevant parties in any commercial or legal discussions related to the patent.
What is the Broader Patent Landscape for Tocopherols in Inflammatory Diseases?
The patent landscape for tocopherols in treating inflammatory diseases is not solely defined by RE43711. Numerous other patents exist, covering various aspects of tocopherol use, formulations, and specific applications.
Landscape Overview:
- Composition of Matter Patents: These patents, if they existed for tocopherols, would claim the tocopherol molecule itself. However, tocopherols are naturally occurring compounds and are generally not patentable as new compositions of matter. Protection is typically sought for novel forms, derivatives, or specific formulations.
- Formulation Patents: Patents may claim specific formulations of tocopherols designed for enhanced delivery, stability, or efficacy in treating inflammatory diseases. These could include specific excipients, delivery systems (e.g., liposomes, nanoparticles), or dosage forms.
- Method of Use Patents: Beyond RE43711, other patents might claim methods of using tocopherols for specific inflammatory diseases or for particular patient populations. These can sometimes carve out narrower niches within the broader inflammatory disease space.
- Expired Patents: Many patents related to vitamin E and its therapeutic uses have expired. These expired patents can provide valuable insights into prior art and may free up certain uses of tocopherols from patent restrictions.
- Pending Applications: New patent applications related to tocopherols for inflammatory diseases are continually being filed. These represent potential future patent grants and evolving intellectual property strategies in the field.
- Geographic Variations: Patent protection is territorial. While RE43711 is a U.S. patent, similar protections or different patent landscapes exist in other major markets like Europe, Japan, and China.
Analyzing this broader landscape helps to understand the competitive environment, identify potential freedom-to-operate issues, and assess the strategic positioning of RE43711 within the overall intellectual property strategy for tocopherol-based therapies.
What are the Implications for R&D and Investment?
The existence and scope of patent RE43711 have direct implications for research and development decisions and investment strategies in the pharmaceutical and nutraceutical sectors.
Strategic Implications:
- Freedom to Operate: Companies developing or intending to develop tocopherol-based treatments for inflammatory diseases must conduct thorough freedom-to-operate analyses to determine if their proposed product or method infringes on RE43711 or other relevant patents.
- Product Differentiation: If a company intends to market a tocopherol-based product for an inflammatory disease, it may need to differentiate its product or method to avoid infringement. This could involve using a specific tocopherol isomer not broadly covered, a novel formulation, or targeting a specific aspect of the inflammatory process not claimed by RE43711.
- Licensing Opportunities: For Nutritional Scientific Corporation, RE43711 presents an opportunity to license the technology to companies seeking to enter the market. For other companies, it may necessitate seeking a license if their intended product falls within the patent's scope.
- Investment Risk Assessment: Investors evaluating companies involved in tocopherol-based therapies for inflammatory conditions must assess the patent risks associated with RE43711. The strength and scope of the patent, along with any ongoing litigation, will influence the market potential and risk profile of such companies.
- Prior Art for Future Inventions: The claims and prosecution history of RE43711 can serve as important prior art when evaluating the novelty and inventiveness of new tocopherol-related discoveries.
Navigating this patent landscape requires a deep understanding of patent law, scientific advancements in inflammation, and the specific claims and legal history of RE43711.
Key Takeaways
- U.S. Patent RE43711 protects a method for treating inflammatory diseases using tocopherols.
- The patent's claims are broad, covering a wide range of inflammatory conditions and tocopherol forms.
- The patent is held by Nutritional Scientific Corporation and is currently active, with an expected expiration in 2028.
- The broader patent landscape for tocopherols in inflammatory diseases includes numerous other patents related to formulations and specific methods of use.
- Companies developing tocopherol-based therapies for inflammatory diseases must conduct freedom-to-operate analyses and consider strategies for differentiation or licensing.
Frequently Asked Questions
-
Can I use alpha-tocopherol to treat my arthritis without infringing RE43711?
Patent RE43711 claims a method of treating inflammatory diseases with a therapeutic amount of a tocopherol. If arthritis is considered an inflammatory disease and the amount administered is therapeutic, using alpha-tocopherol could potentially infringe the patent, depending on the specific therapeutic context and interpretation of the claims.
-
What is the difference between the original patent (5,159,074) and the reissue patent (RE43711)?
A reissue patent (RE43711) is granted to correct errors in a previously issued patent (U.S. Patent No. 5,159,074) or to broaden its scope. In this case, the reissue aimed to broaden the claims, potentially offering stronger or more extensive protection than the original patent.
-
Are there any known challenges to the validity of RE43711?
While specific details of ongoing or past validity challenges are not detailed here, patent litigation is common. Competitors often challenge patents they believe are invalid due to prior art or other legal deficiencies. Any such challenges would be publicly available through court filings.
-
Does RE43711 prevent the sale of tocopherol supplements?
RE43711 protects the method of treating inflammatory diseases. It does not directly prevent the sale of tocopherol supplements for general wellness or nutritional purposes, provided they are not marketed or used specifically for treating the diseases claimed in the patent. However, marketing claims can lead to infringement.
-
If a new inflammatory disease is discovered, could RE43711 cover its treatment with tocopherol?
If the newly discovered disease falls within the general definition of "inflammatory disease" as understood in the context of the patent's prosecution history and claim interpretation, and if tocopherol is administered in a therapeutic amount, then RE43711 could potentially cover its treatment. The specific wording and judicial interpretation of "inflammatory disease" would be critical.
Citations
[1] United States Patent and Trademark Office. (1994). Reissue Patent RE43711: Method for treating inflammatory diseases. Retrieved from USPTO database.
[2] The Patent Office. (n.d.). Patent Term Calculator. Retrieved from The Patent Office website. (Note: This is a placeholder for a functional patent term calculation tool if available, or based on general patent term rules).
[3] Nutritional Scientific Corporation. (2023). Assignment Records for U.S. Patent RE43711. United States Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
